DK2833910T3 - PCV/mycoplasma hyopneumoniae-kombinationsvaccine - Google Patents
PCV/mycoplasma hyopneumoniae-kombinationsvaccine Download PDFInfo
- Publication number
- DK2833910T3 DK2833910T3 DK13718432.1T DK13718432T DK2833910T3 DK 2833910 T3 DK2833910 T3 DK 2833910T3 DK 13718432 T DK13718432 T DK 13718432T DK 2833910 T3 DK2833910 T3 DK 2833910T3
- Authority
- DK
- Denmark
- Prior art keywords
- hyo
- pcv2
- antigen
- composition
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Claims (16)
1. Multivalent immunogen sammensætning omfattende supernatanten af en Mycoplasma hyopneumoniae (M.hyo)-kultur; et porcint circovirus type 2 (PCV2)-antigen; hvor supernatanten af M.hyo-kulturen er blevet separeret fra uopløseligt cellulært materiale ved centrifugering, filtrering eller udfældning og er fri for både (i) IgG og (ii) immunkomplekser bestående af antigen, der er bundet til immunglobulin.
2. Sammensætning ifølge krav 1, hvor supernatanten af M.hyo-kulturen er blevet behandlet med protein-A eller protein-G, før den blev tilsat til den immunogene sammensætning.
3. Sammensætning ifølge et af kravene 1 til 2, hvor PCV2-antigenet er i form af et kimært type 1-type 2-circovirus, hvilket kimære virus omfatter et inaktive-ret rekombinant porcint circovirus type 1, der eksprimerer det porcine circovirus type 2-ORF2-protein.
4. Sammensætning ifølge et af kravene 1 til 3, hvor PCV2-antigenet er i form af et rekombinant ORF2-protein.
5. Sammensætning ifølge krav 4, hvor det rekombinante ORF2-protein ekspri-meres fra en baculovirusvektor.
6. Sammensætning ifølge et af kravene 1 til 5, endvidere omfattende mindst et yderligere antigen, der beskytter mod en mikroorganisme, der kan forårsage sygdom hos grise, hvor mikroorganismen er valgt fra gruppen bestående af porcin reproduktiv og respiratorisk syndromvirus (PRRSV), porcin parvovirus (PPV), haemophilus parasuis, pasteurella multocida, streptococcum suis, staphylococcus hyicus, actinobacilllus pleuropneumoniae, bordetella bronchi-septica, salmonella choleraesuis, salmonella enteritidis, erysipelothrix rhusio-pathiae, mycoplasma hyorhinis, mycoplasma hyosynoviae, leptospirabakterie, lawsonia intracellularis, svineinfluenzavirus (SIV), escherichia co//-antigen, brachyspira hyodysenteriae, porcin respiratorisk coronavirus, porcin epidemisk diarré (PED)-virus, rotavirus, torque teno-virus (TTV), porcin cytomega- lovirus, porcine enterovira, encephalomyocarditis-virus, et patogen, der forårsager Aujeskys sygdom, klassisk svinefeber (CSF), og et patogen, der forårsager overførbar svinegastroenteritis eller kombinationer deraf.
7. Sammensætning ifølge et af kravene 1 til 6, hvor sammensætningen endvidere omfatter en adjuvans.
8. Sammensætning ifølge krav 7, hvor adjuvansen er valgt fra gruppen bestående afen olie-i-vand-adjuvans, en polymer-og-vand-adjuvans, en vand-i-olie-adjuvans, en aluminiumhydroxid-adjuvans, en E-vitamin-adjuvans og kombinationer deraf.
9. Sammensætning ifølge et af kravene 1 til 8 til anvendelse ved immunisering af en gris imod Mycoplasma hyopneumoniae (M.hyo) og PCV2, som omfatter indgivelse af sammensætningen ifølge krav 1 til 8 til grisen.
10. Sammensætning til anvendelse ifølge krav 9, hvor sammensætningen indgives i en enkelt dosis.
11. Sammensætning til anvendelse ifølge krav 9 eller 10, hvor sammensætningen indgives til grise, som har maternelt afledte antistoffer mod mindst en af M.hyo og PCV2 eller både M.hyo og PCV2.
12. Sammensætning til anvendelse ifølge et af kravene 9 til 11, hvor sammensætningen indgives til grise, når de er er 3 uger gamle eller ældre.
13. Vaccinesammensætning omfattende en immunogen sammensætning ifølge et af kravene 1 til 8, hvor sammensætningen endvidere omfatter en farmaceutisk acceptabel bærer.
14. Vaccinesammensætning ifølge krav 13 til anvendelse til beskyttelse af grise imod enzootisk pneumoni, PMWS (Post-weaning Multisystemic Wasting Syndrome).
15. Kit omfattende: en flaske omfattende en immunogen sammensætning eller vaccinesammensætning indeholdende både et PCV2-antigen og supernatan-ten af en Mycoplasma hyopneumoniae (M.hyo)-kultur, hvor supernatanten er fri for både (i) IgG og (ii) antigen/immunoglobulin-immunokomplekser ifølge et af kravene 1 til 14, og eventuelt endvidere omfattende en instruktionsmanual, der indeholder information til at administrere den immunogene sammensætning.
16. Fremgangsmåde til fremstilling af en immunogen sammensætning ifølge et af kravene 1 til 14, hvilken fremgangsmåde omfatter: i) at dyrke M.hyo i et egnet medium over tidsrum på fra 18-144 timer; ii) efterfølgende at inaktivere M.hyo-kulturen; iii) at høste den inaktiverede kulturfluid, hvor den inaktiverede kulturfluid omfatter både en opløselig væskefraktion og uopløseligt cellulært materiale; iv) at separere den opløselige væskefraktion fra det uopløselige cellulære materiale ved filtrering, centrifugering eller udfældning; v) at fjerne både IgG og antigen/immunglobulin-immunkomplekserfra den fraseparerede opløselige væskefraktion til dannelse af M. hyo-kultur-supernatan-ten, der er fri for både (i) IgG og (ii) immunkomplekser bestående af antigen, der er bundet til immunglobulin; og vi) efterfølgende at kombinere supernatanten med et PCV2-antigen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261620175P | 2012-04-04 | 2012-04-04 | |
PCT/US2013/035088 WO2013152083A2 (en) | 2012-04-04 | 2013-04-03 | Pcv/mycoplasma hyopneumoniae combination vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2833910T3 true DK2833910T3 (da) | 2019-04-15 |
Family
ID=48182999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13718432.1T DK2833910T3 (da) | 2012-04-04 | 2013-04-03 | PCV/mycoplasma hyopneumoniae-kombinationsvaccine |
Country Status (33)
Country | Link |
---|---|
US (5) | US9125885B2 (da) |
EP (2) | EP2833910B1 (da) |
JP (1) | JP6271503B2 (da) |
KR (3) | KR20150003259A (da) |
CN (1) | CN104334186B (da) |
AR (1) | AR090615A1 (da) |
AU (1) | AU2013243537B2 (da) |
BR (1) | BR112014024785B1 (da) |
CA (1) | CA2869594C (da) |
CL (1) | CL2014002675A1 (da) |
CO (1) | CO7160025A2 (da) |
CR (1) | CR20140437A (da) |
CY (1) | CY1121998T1 (da) |
DK (1) | DK2833910T3 (da) |
ES (1) | ES2721925T3 (da) |
HK (1) | HK1206609A1 (da) |
HR (2) | HRP20140954A2 (da) |
HU (1) | HUE043322T2 (da) |
LT (1) | LT2833910T (da) |
MX (2) | MX336503B (da) |
MY (1) | MY174622A (da) |
NI (1) | NI201400119A (da) |
PH (1) | PH12014502251B1 (da) |
PL (1) | PL2833910T3 (da) |
PT (1) | PT2833910T (da) |
RS (1) | RS58481B1 (da) |
RU (1) | RU2615443C2 (da) |
SI (1) | SI2833910T1 (da) |
TR (1) | TR201904603T4 (da) |
TW (1) | TWI602574B (da) |
UA (1) | UA114503C2 (da) |
WO (1) | WO2013152083A2 (da) |
ZA (1) | ZA201406974B (da) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9120859B2 (en) | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
UA114504C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
UA114503C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
EP2938356B1 (en) * | 2012-12-28 | 2020-05-13 | Boehringer Ingelheim Vetmedica GmbH | Immunogenic composition comprising mycoplasma antigens |
CN104968365B (zh) | 2012-12-28 | 2018-04-03 | 勃林格殷格翰动物保健有限公司 | 支原体疫苗的制备方法 |
EP2994162B1 (en) | 2013-05-08 | 2021-04-07 | Pharmgate Biologics Inc. | Vaccine for pcv2 and mycoplasma |
CN104248759B (zh) * | 2013-11-19 | 2017-05-10 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
CA2931136C (en) * | 2013-12-03 | 2023-03-21 | Intervet International B.V. | Vaccine against lawsonia intracellularis and porcine circovirus 2 |
RU2712155C2 (ru) * | 2013-12-03 | 2020-01-24 | Интервет Интернэшнл Б.В. | Вакцина против цирковируса свиней 2 типа |
US9713639B2 (en) * | 2014-05-19 | 2017-07-25 | Merial, Inc. | Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (PEDV) |
RU2731845C2 (ru) * | 2014-12-11 | 2020-09-08 | Интервет Интернэшнл Б.В. | СПОСОБ ПОЛУЧЕНИЯ ГОТОВОЙ К ПРИМЕНЕНИЮ КОМБИНИРОВАННОЙ ВАКЦИНЫ ПРОТИВ PCV2/M.hyo |
WO2017162741A1 (en) * | 2016-03-23 | 2017-09-28 | Intervet International B.V. | A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection |
JP2019512518A (ja) * | 2016-03-23 | 2019-05-16 | インターベット インターナショナル ベー. フェー. | Pcv2およびprrsウイルス感染に対する皮内適用のためのワクチン |
KR102632419B1 (ko) | 2016-12-23 | 2024-01-31 | 인터벳 인터내셔널 비.브이. | 돼지용 조합 백신 |
CN106668855B (zh) * | 2017-02-03 | 2020-11-24 | 四川省华派生物制药有限公司 | 猪肺炎支原体灭活疫苗与猪瘟活疫苗组合疫苗及其制备方法 |
EP4335455A2 (en) * | 2017-04-13 | 2024-03-13 | Intervet International B.V. | Vaccines containing swine pathogens for associated non-mixed use |
CN109010818B (zh) | 2017-06-09 | 2021-11-09 | 普莱柯生物工程股份有限公司 | 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用 |
CN109125719B (zh) * | 2017-06-19 | 2022-06-14 | 普莱柯生物工程股份有限公司 | 一种含猪圆环病毒3型、猪圆环病毒2型抗原的免疫原性组合物及其应用 |
CN109207502B (zh) * | 2018-10-10 | 2021-08-10 | 浙江洪晟生物科技股份有限公司 | 猪支原体肺炎和猪圆环病毒2型重组蛋白及制备二联疫苗 |
CN109234418B (zh) * | 2018-11-20 | 2021-08-13 | 湖南中净生物科技有限公司 | 一种鉴别猪肺炎支原体野毒株和疫苗株的引物、试剂盒和方法 |
CN112294953A (zh) * | 2020-12-31 | 2021-02-02 | 北京科牧丰生物制药有限公司 | 一种pcv2型杆状病毒载体、猪肺炎支原体、副猪嗜血杆菌三联灭活疫苗及制备方法 |
KR102646305B1 (ko) * | 2021-03-04 | 2024-03-13 | 주식회사 이노백 | 돼지 마이코플라스마균 및 돼지 써코바이러스 감염 예방을 위한 다가 백신 조성물 |
WO2022186661A1 (ko) * | 2021-03-04 | 2022-09-09 | 주식회사 이노백 | 돼지 마이코플라스마균 및 돼지 써코바이러스 감염 예방을 위한 다가 백신 조성물 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB228811A (en) | 1924-11-04 | 1925-02-12 | Congoleum Company Inc | Improvements in stands or racks for displaying rolled merchandise |
US4606918A (en) | 1983-08-22 | 1986-08-19 | Syntex (U.S.A.) Inc. | Polyoxypropylene-polyoxyethylene block polymer based adjuvants |
US4681870A (en) * | 1985-01-11 | 1987-07-21 | Imre Corporation | Protein A-silica immunoadsorbent and process for its production |
JPH0832637B2 (ja) | 1985-02-14 | 1996-03-29 | アクゾ・エヌ・ヴエー | 合成免疫原 |
US5084269A (en) | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
EP0283085B1 (en) | 1987-03-17 | 1992-11-11 | Akzo N.V. | Adjuvant mixture |
US5252328A (en) | 1987-03-26 | 1993-10-12 | Martin Marietta Energy Systems, Inc. | Mycoplasma hyopneumoniae antigen and uses therefor |
EP0283840A3 (en) | 1987-03-26 | 1989-08-09 | Ml Technology Ventures, L.P. | Mycoplasma hyopneumoniae antigen and uses therefor |
ES2052674T3 (es) | 1987-11-03 | 1994-07-16 | Syntex Inc | Adyuvante de vacunas. |
US4985243A (en) | 1988-01-20 | 1991-01-15 | Ml Technology Ventures, L.P. | Composition and method for protecting against diseases caused by microorganisms |
US5240706A (en) | 1989-04-07 | 1993-08-31 | Ml Technology Ventures, L.P. | Intranasal administration of Mycoplasma hyopneumoniae antigen |
ZA906806B (en) | 1989-08-31 | 1991-06-26 | Ici Australia Operations | Plants |
US6113916A (en) | 1990-05-29 | 2000-09-05 | American Cyanamid Company | Method of enhancing cell mediated immune responses |
EP0597852B2 (en) | 1990-05-29 | 2005-08-10 | Wyeth Holdings Corporation | Swine pneumonia vaccine and method for the preparation thereof |
US5695769A (en) | 1990-06-13 | 1997-12-09 | Pfizer Inc. | Pasteurella multocida toxoid vaccines |
US5565205A (en) | 1990-08-16 | 1996-10-15 | Solvay Animal Health, Inc. | Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof |
DK0587780T4 (da) | 1991-06-06 | 2008-10-13 | Boehringer Ingelheim Vetmed | Smitstof, som forårsager Mystery Swine Disease,vaccinepræparater og diagnostiske sæt |
DE601062T1 (de) | 1991-08-26 | 1995-05-18 | James Edward Collins | Vakzine gegen und diagnosemethode für das schweine-unfruchtbarkeits- und atmungs-syndrom (suas). |
JPH07501049A (ja) | 1991-10-14 | 1995-02-02 | アクゾ・ノベル・エヌ・ベー | ブタ生殖・呼吸系症候群ワクチン及び診断方法 |
US5616328A (en) | 1991-11-15 | 1997-04-01 | Pfizer Inc. | Method of preparing gram-negative bacterial vaccines |
FR2686097B1 (fr) | 1992-01-14 | 1994-12-30 | Rhone Merieux | Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie. |
US5338543A (en) | 1992-02-27 | 1994-08-16 | Ambico, Inc. | Thimerosal inactivated mycoplasma hyopneumoniae vaccine |
US5534256A (en) | 1992-07-02 | 1996-07-09 | University Of Saskatchewan | Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins |
US5695766A (en) | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
US6592873B1 (en) | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
US6773908B1 (en) | 1992-10-30 | 2004-08-10 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
US6251397B1 (en) | 1992-10-30 | 2001-06-26 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same |
US6380376B1 (en) | 1992-10-30 | 2002-04-30 | Iowa State University Research Foundation | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
ES2074950B1 (es) | 1993-09-17 | 1996-03-16 | Iberica Cyanamid | Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda. |
DE69535520T2 (de) | 1994-05-10 | 2008-02-07 | Wyeth | Abgeänderter, verbesserter BRSV Lebend- Impfstoff |
BE1008978A5 (fr) | 1994-12-27 | 1996-10-01 | Solvay | Adjuvants pour vaccins. |
US5788962A (en) | 1995-01-17 | 1998-08-04 | The Curators Of The University Of Missouri | DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures |
AUPN178995A0 (en) | 1995-03-16 | 1995-04-13 | University Of Melbourne, The | Antigen composition |
US5820869A (en) | 1995-06-07 | 1998-10-13 | American Home Products Corporation | Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
DE19601754A1 (de) | 1996-01-19 | 1997-07-24 | Hoechst Ag | Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung |
US5846735A (en) | 1996-04-18 | 1998-12-08 | University Of Iowa Research Foundation | Hepatitis C virus Fc-binding function |
GB9622159D0 (en) | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
AU746442B2 (en) | 1996-12-20 | 2002-05-02 | Board Of Regents, The University Of Texas System | UspA1 and UspA2 antigens of Moraxella catarrhalis |
KR20010032493A (ko) | 1997-11-26 | 2001-04-25 | 아이오와 스테이트 유니버시티 리서치 파운데이션, 인코퍼레이티드 | 재조합 미코플라스마 히오뉴모니아(Mycoplasmahyopneumoniae) 백신 |
FR2772047B1 (fr) | 1997-12-05 | 2004-04-09 | Ct Nat D Etudes Veterinaires E | Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection |
US6342231B1 (en) | 1998-07-01 | 2002-01-29 | Akzo Nobel N.V. | Haemophilus parasuis vaccine and diagnostic |
CA2290220C (en) | 1998-12-22 | 2013-11-19 | Pfizer Products Inc. | An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof |
US6632439B2 (en) | 1999-09-29 | 2003-10-14 | Novartis Animal Health, Inc. | Fusobacterium necrophorum vaccine and method for making such vaccine |
US6585981B1 (en) | 2000-07-27 | 2003-07-01 | Regents Of The University Of Minnesota | Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae |
MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
US7018638B2 (en) | 2000-12-19 | 2006-03-28 | Wyeth | Mycoplasma hyopneumoniae bacterin vaccine |
CA2452666A1 (en) * | 2001-07-02 | 2003-01-16 | Pfizer Products Inc. | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
ATE412426T2 (de) | 2001-07-02 | 2008-11-15 | Pfizer Prod Inc | Vakzination in einer dosis mit i mycoplasma hyopneumoniae /i |
US7279166B2 (en) * | 2001-12-12 | 2007-10-09 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
US7276353B2 (en) | 2001-12-12 | 2007-10-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof |
EP1546357B1 (en) | 2002-06-28 | 2013-08-07 | Iowa State University Research Foundation, Inc. | Immunogenic mycoplasma hyopneumoniae polypeptides |
MXPA06000942A (es) * | 2003-07-24 | 2006-03-30 | Merial Ltd | Nuevas formulaciones de vacunas. |
KR20070096019A (ko) | 2005-01-13 | 2007-10-01 | 베링거잉겔하임베트메디카게엠베하 | 향상된 prrs 백신 |
BRPI0615862A2 (pt) * | 2005-09-09 | 2011-05-31 | Intervet Int Bv | vacina contra pcv-2, e, método para a manufatura de uma vacina |
EP1792996A1 (en) | 2005-12-01 | 2007-06-06 | Consejo Superior de Investigaciones Cientificas | Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV) |
HUE054868T2 (hu) | 2005-12-29 | 2021-10-28 | Boehringer Ingelheim Animal Health Usa Inc | Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására |
DK2371383T3 (da) * | 2005-12-29 | 2015-11-30 | Boehringer Ingelheim Vetmed | Anvendelse af en PCV2-immunogen sammensætning til mindskning af kliniske symptomer i grise |
WO2007116032A1 (en) | 2006-04-10 | 2007-10-18 | Intervet International B.V. | Vaccine against mycoplasma prrsv |
BRPI0710550A2 (pt) * | 2006-04-10 | 2011-08-16 | Intervet Int Bv | uso de uma dose imunogênica de material imunogênico de mycoplasma hyopneumoniae e uma dose imunogênica de vìrus de prrs atenuado vivo, kit de vacina, e, método para a vacinação de porcos |
RU2520087C2 (ru) * | 2006-12-15 | 2014-06-20 | Бёрингер Ингельхайм Ветмедика, Инк. | Лечение свиней с помощью антигена pcv2 |
MX2010005014A (es) * | 2007-11-06 | 2010-06-30 | Wyeth Llc | Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante. |
US20090317423A1 (en) | 2008-01-23 | 2009-12-24 | Boehringer Ingelheim Vetmedica, Inc. | Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions |
TWI449533B (zh) | 2008-04-18 | 2014-08-21 | Intervet Int Bv | 防備胞內勞森菌(Lawsonia intracellularis)、豬肺炎黴漿菌(Mycoplasma hyopneumoniae)及豬環狀病毒(Porcine circo virus)用疫苗 |
US8444989B1 (en) | 2008-04-18 | 2013-05-21 | Boehringer Ingelheim Vetmedica Gmbh | One dose vaccination against mycoplasma infections of pigs |
WO2010044889A2 (en) | 2008-10-16 | 2010-04-22 | Pfizer Inc. | Torque teno virus (ttv) isolates and compositions |
FI20096134A0 (fi) | 2009-11-03 | 2009-11-03 | Pulse Finland Oy | Säädettävä antenni |
WO2011141443A1 (en) | 2010-05-11 | 2011-11-17 | Intervet International B.V. | Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies |
US8546149B2 (en) | 2010-08-27 | 2013-10-01 | Intervet Inc. | Potency test for vaccine formulations |
BR112013004594B1 (pt) * | 2010-08-27 | 2020-07-28 | Intervet International B. V. | método para a determinação de um conteúdo de antígeno |
UA108902C2 (uk) | 2010-11-10 | 2015-06-25 | Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування | |
BR112014022067B1 (pt) | 2012-03-07 | 2022-05-31 | Ceva Sante Animale | Composição compreendendo antígeno e lipopolissacarídeo |
UA114504C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs |
US9120859B2 (en) * | 2012-04-04 | 2015-09-01 | Zoetis Services Llc | Mycoplasma hyopneumoniae vaccine |
UA114503C2 (uk) * | 2012-04-04 | 2017-06-26 | Зоетіс Сервісіз Ллс | Комбінована вакцина pcv та mycoplasma hyopneumoniae |
-
2013
- 2013-03-04 UA UAA201410838A patent/UA114503C2/uk unknown
- 2013-03-26 US US13/850,329 patent/US9125885B2/en active Active
- 2013-04-02 TW TW102111966A patent/TWI602574B/zh active
- 2013-04-03 JP JP2015504699A patent/JP6271503B2/ja active Active
- 2013-04-03 KR KR20147030865A patent/KR20150003259A/ko not_active Application Discontinuation
- 2013-04-03 EP EP13718432.1A patent/EP2833910B1/en active Active
- 2013-04-03 KR KR1020187012298A patent/KR20180049221A/ko not_active Application Discontinuation
- 2013-04-03 HU HUE13718432A patent/HUE043322T2/hu unknown
- 2013-04-03 WO PCT/US2013/035088 patent/WO2013152083A2/en active Application Filing
- 2013-04-03 CN CN201380023651.6A patent/CN104334186B/zh active Active
- 2013-04-03 MY MYPI2014702901A patent/MY174622A/en unknown
- 2013-04-03 DK DK13718432.1T patent/DK2833910T3/da active
- 2013-04-03 AU AU2013243537A patent/AU2013243537B2/en active Active
- 2013-04-03 TR TR2019/04603T patent/TR201904603T4/tr unknown
- 2013-04-03 ES ES13718432T patent/ES2721925T3/es active Active
- 2013-04-03 BR BR112014024785-4A patent/BR112014024785B1/pt active IP Right Grant
- 2013-04-03 PL PL13718432T patent/PL2833910T3/pl unknown
- 2013-04-03 RS RS20190382A patent/RS58481B1/sr unknown
- 2013-04-03 RU RU2014140106A patent/RU2615443C2/ru active
- 2013-04-03 CA CA2869594A patent/CA2869594C/en active Active
- 2013-04-03 EP EP19156797.3A patent/EP3508218A1/en active Pending
- 2013-04-03 KR KR1020177011554A patent/KR102003620B1/ko active IP Right Grant
- 2013-04-03 LT LTEP13718432.1T patent/LT2833910T/lt unknown
- 2013-04-03 MX MX2014012015A patent/MX336503B/es unknown
- 2013-04-03 PT PT13718432T patent/PT2833910T/pt unknown
- 2013-04-03 SI SI201331403T patent/SI2833910T1/sl unknown
- 2013-04-04 AR ARP130101116 patent/AR090615A1/es not_active Application Discontinuation
-
2014
- 2014-09-22 CR CR20140437A patent/CR20140437A/es unknown
- 2014-09-23 ZA ZA2014/06974A patent/ZA201406974B/en unknown
- 2014-10-03 HR HRP20140954AA patent/HRP20140954A2/hr not_active Application Discontinuation
- 2014-10-03 NI NI201400119A patent/NI201400119A/es unknown
- 2014-10-03 PH PH12014502251A patent/PH12014502251B1/en unknown
- 2014-10-03 CL CL2014002675A patent/CL2014002675A1/es unknown
- 2014-10-03 CO CO14219838A patent/CO7160025A2/es unknown
- 2014-10-03 MX MX2015015486A patent/MX354759B/es unknown
-
2015
- 2015-05-14 US US14/712,426 patent/US9649369B2/en active Active
- 2015-07-27 HK HK15107171.9A patent/HK1206609A1/xx unknown
-
2017
- 2017-04-06 US US15/480,973 patent/US10206993B2/en active Active
-
2019
- 2019-01-15 US US16/248,239 patent/US10668145B2/en active Active
- 2019-03-22 HR HRP20190563TT patent/HRP20190563T1/hr unknown
- 2019-04-24 CY CY20191100446T patent/CY1121998T1/el unknown
-
2020
- 2020-04-28 US US16/860,308 patent/US11154609B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11154609B2 (en) | PCV/mycoplasma hyopneumoniae vaccine | |
US11141472B2 (en) | Mycoplasma hyopneumoniae vaccine | |
US9650601B2 (en) | PCV/mycoplasma hyopneumoniae/PRRS combination vaccine |